Secure Asset Management LLC Acquires 7,788 Shares of BioMarin Pharmaceutical Inc. $BMRN

Secure Asset Management LLC raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 11.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 78,208 shares of the biotechnology company’s stock after acquiring an additional 7,788 shares during the quarter. Secure Asset Management LLC’s holdings in BioMarin Pharmaceutical were worth $4,475,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of BioMarin Pharmaceutical during the 2nd quarter valued at $39,000. CIBC Private Wealth Group LLC boosted its holdings in BioMarin Pharmaceutical by 38.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 179 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in BioMarin Pharmaceutical in the third quarter worth $40,000. Parallel Advisors LLC increased its position in BioMarin Pharmaceutical by 62.2% during the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock worth $42,000 after buying an additional 295 shares during the last quarter. Finally, Keating Financial Advisory Services Inc. acquired a new position in BioMarin Pharmaceutical during the second quarter worth $56,000. 98.71% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Morgan Stanley boosted their price target on BioMarin Pharmaceutical from $119.00 to $124.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Barclays increased their price objective on BioMarin Pharmaceutical from $105.00 to $111.00 and gave the company an “overweight” rating in a report on Monday, August 17th. Royal Bank Of Canada reduced their target price on BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. Oppenheimer upped their target price on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the stock an “outperform” rating in a research report on Friday, August 7th. Finally, Citigroup increased their price target on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $89.00.

Key BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Patent settlement adds potential royalty revenue: BioMarin reached a global agreement with Ascendis Pharma resolving patent disputes over Yuviwel. Ascendis will pay BioMarin royalties on Yuviwel sales in the U.S., European Union, Brazil and South Korea, removing a legal overhang and creating a potential recurring revenue stream. BioMarin Announces Global Settlement with Ascendis Pharma
• Positive Sentiment: Alesta acquisition expands the pipeline: BioMarin completed its acquisition of Dutch biotech Alesta Therapeutics. The deal adds ALE1, a potential first oral treatment for hypophosphatasia, giving investors another clinical catalyst and potentially broadening treatment options beyond BioMarin’s existing portfolio. BioMarin Announces Close of the Alesta Therapeutics Acquisition
• Positive Sentiment: Analyst targets moved higher: Piper Sandler raised its target from $88 to $90 and maintained an “overweight” rating. Jefferies also increased its target from $104 to $105 and kept a “buy” rating, indicating substantial potential upside based on analysts’ expectations. Analyst price target updates
• Neutral Sentiment: Rare-disease growth thesis remains intact: Zacks highlighted BMRN among rare-disease drugmakers with long-term growth potential, citing its products, pipeline catalysts and significant unmet medical needs. This supports the broader investment case but is not a new company-specific operating update. 4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
• Negative Sentiment: One analyst remains cautious: HC Wainwright raised its target modestly from $59 to $60 but retained a “neutral” rating, with the target below the recent trading level. This signals that some analysts view the stock’s valuation and near-term upside as limited. Analyst price target update

BioMarin Pharmaceutical Stock Down 0.6%

BMRN stock opened at $64.84 on Wednesday. The stock has a market capitalization of $12.55 billion, a price-to-earnings ratio of 175.24, a price-to-earnings-growth ratio of 0.47 and a beta of 0.24. The company has a 50-day moving average of $62.05 and a two-hundred day moving average of $58.22. BioMarin Pharmaceutical Inc. has a 52-week low of $49.26 and a 52-week high of $70.98. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The business had revenue of $989.71 million for the quarter, compared to analyst estimates of $932.03 million. During the same period in the previous year, the company posted $1.44 earnings per share. The firm’s revenue for the quarter was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, equities research analysts anticipate that BioMarin Pharmaceutical Inc. will post 4.1 EPS for the current year.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.